OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Haematology is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Towards reparatory measures: blood donation, health systems, and men who have sex with men	230
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?	214
In the trenches	182
Zanubrutinib-associated ecchymotic lesions	178
“I can't breathe”: how sickle cell disease manifests in the USA today	167
Prioritising health equity alongside donation safety – Authors' reply	148
Trials and tribulations: including women in cancer clinical research	142
Will the changing therapeutic landscape meet the needs of patients with sickle cell disease?	138
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?	132
Retinal haemorrhage as a complication of blastic plasmacytoid dendritic cell neoplasm	117
Correction to Lancet Haematol 2023; 10: e333–45	113
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3	112
Correction to Lancet Haematol 2024; 11: e114–26	111
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts	111
Managing haematological malignancies in pregnant women	100
MRD-guided treatment cessation in multiple myeloma	98
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries	97
Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?	97
Vaccine efficacy and iron deficiency: an intertwined pair?	93
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial	83
International Society on Thrombosis and Haemostasis Congress 2023	82
Be compliant or compromise?	82
The HemeOncBuddy app—a new tool to keep up with the clinical trial storm	81
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia	81
Bedside art is good medicine	80

Artwork from trauma: the social life of medical data	79
Sequencing therapies in Hodgkin lymphoma	73
CAR T cells in CNS-relapsed leukaemia: one step forward	70
Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia	68
Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial	66
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	66
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study	66
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past	66
Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study	65
COVID-19 vaccines for patients with haematological conditions	65
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective	62
Racial and ethnic survival disparities in patients with haematological malignancies in the USA: time to stop ignoring the numbers	62
Blood deserts: a vision to tackle blood inaccessibility	61
Living with sickle cell disease: voices from sub-Saharan Africa	58
Blood cell defence against pathogens	58
25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial	57
Correction to Lancet Haematol 2023; 10: e433–44	56
Call to action: equitable comprehensive care for patients with sickle cell disease in the USA	54
Production and supply of blood products in Brazil	54
Correction to Lancet Haematol 2021; 8: e205–15	54
Eltrombopag–cyclosporin A in treating severe aplastic anaemia	54
Sickle cell disease in India: current status and progress	53
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations	53
Rituximab versus active surveillance in patients with follicular lymphoma	52
Methodological challenges in the development of endpoints for myelofibrosis clinical trials	50
Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health	50
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study	50